Topics

High-grade gliomas | Treatment | Immunotherapy | CAR-T-Cells

Home > Publications > Topics > High-grade gliomas > Treatment > Immunotherapy > CAR-T-Cells

Gallus M, Young JS, Cook Quackenbush S, Khasraw M, de Groot J, Okada H.
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.
Neuro Oncol. 2024 Oct 24:noae203. doi: 10.1093/neuonc/noae203. PMID: 39450490. Review. ˍ

Grewal EP, Nahed BV, Carter BS, Gerstner ER, Curry WT, Maus MV, Choi BD.
Clinical progress in the development of CAR T cells to treat malignant glioma.
J Neurooncol. 2024 Dec 18. doi: 10.1007/s11060-024-04909-7. PMID: 39695004. Interventional; Review˰ ˍ

Park S, Maus MV, Choi BD.
CAR-T cell therapy for the treatment of adult high-grade gliomas.
NPJ Precis Oncol. 2024 Dec 19;8(1):279. doi: 10.1038/s41698-024-00753-0. PMID: 39702579. Review. ˍ

**Gu J, Li J, Xu Y, Zhang G, Xie J, Jia R, Chen W, Lu Z, Chang C, Wen H, Chang LJ, Ma H, Cai Q.
Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas.
J Transl Med. 2025 May 27;23(1):591. doi: 10.1186/s12967-025-06523-1. PMID: 40420236. Interventional study. ˍ

Parekh D, Patel AH, Khan A, Olojakpoke E, Karpe A, Peelay Z, Patil V.
CAR-T in relapsed refractory high-grade glioma and glioblastoma - who, what, when and how?
Ecancermedicalscience. 2025 Sep 30;19:2001. doi: 10.3332/ecancer.2025.2001. PMID: 41561543. Review. ˍ

Ronsley R, Huang W, Rohlf E, Seidel K, Brown C, Beebe A, Rawlings-Rhea SD, Lindgren C, Sad T, Crotty EE, Leary SES, Thomsen A, Beckstrom AR, Holtzclaw SL, Hoeppner C, Hurst D, MacQuivey M, Goldstein HE, Browd SR, Hauptman JS, Lee A, Ojemann JG, Wright JN, Albert CM, Pinto N, Gustafson JA, Ho O, Pattabhi S, Summers C, Annesley C, Wendler JN, Gust J, Gardner RA, Park JR, Jensen MC, Vitanza NA.
Intracerebroventricular B7-H3-targeting CAR T cells for non-pontine DMG and recurrent/refractory pediatric CNS tumors: a phase 1 trial.
Neuro Oncol. 2026 Jul 25:noag171. doi: 10.1093/neuonc/noag171. PMID: 42503899. Trial registration ID: NCT04185038˰ ˍ

Kim K, Song SW, Jeon Y, Choi S, Choi J, Jun S, Park JH, Lee SJ, Han N, Dho YS, Shin SH, Yoo H, Wang KC, Gwak HS.
Phase I trial of IL13Rα2-targeted CAR-T cell therapy for recurrent malignant glioma: clinical results and pharmacokinetics.
Clin Cancer Res. 2026 Aug 4. doi: 10.1158/1078-0432.CCR-26-0645. PMID: 42550847. Trial registration ID: NCT05540873. ˍ